Form 4: Regeneron CFO Christopher Fenimore Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Christopher R. Fenimore, SVP Finance & CFO of Regeneron Pharmaceuticals, reports disposing of 491 shares of common stock to cover tax obligations.
Summary
- On December 16, 2024, Christopher R. Fenimore, the SVP Finance & CFO of Regeneron Pharmaceuticals, disposed of 491 shares of common stock.
- The transaction was executed at a price of $730.81 per share.
- Following the transaction, Fenimore directly owns 16,265 shares of Regeneron common stock.
- Fenimore also indirectly owns shares through a 401(k) plan (1,515 shares) and trusts (1,897 shares for spouse, 25 shares for daughter, and 25 shares for son).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock transaction by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common among corporate executives. It provides transparency to investors regarding the buying and selling activities of company insiders.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on shareholders, as it is a relatively small number of shares being disposed of by a single executive.
Key Dates
| Date | Description |
|---|---|
| 12/16/2024 | Date of stock disposal transaction |
| 12/18/2024 | Date of signature on the Form 4 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.